

APC mutation associated with familial colorectal cancer in Ashkenazi jews**Publication number:** DE69814622T**Publication date:** 2004-02-26**Inventor:** LAKEN STEVE (US); GRUBER STEPHEN (US); PETERSEN GLORIA (US); KINZLER KENNETH (US); VOGELSTEIN BERT (US)**Applicant:** UNIV JOHNS HOPKINS (US)**Classification:****- international:** C12Q1/68; G01N33/574; C12Q1/68; G01N33/574; (IPC1-7): C12Q1/68; G01N33/574**- european:** C12Q1/68M6B; G01N33/574; G01N33/574C6**Application number:** DE19986014622T 19980121**Priority number(s):** US19970791883 19970131; WO1998US00961 19980121**Also published as:**

WO9833940 (A1)

EP0981644 (A1)

US5879890 (A1)

EP0981644 (A0)

CA2278781 (A1)

more >>

[Report a data error here](#)

Abstract not available for DE69814622T

Abstract of corresponding document: US5879890






During routine screening of a patient with a family history of colorectal cancer for truncating APC mutations, a novel missense mutation was identified. Upon further evaluation, it was found that 6% of Ashkenazi Jews carry this mutation, and that it was present in DIFFERENCE 20% of Ashkenazis with a family history of CRC. Probes, methods, and kits for identifying individuals affected with this missense mutation are provided.

Data supplied from the esp@cenet database - Worldwide

Characterising and identifying disseminated metastatic cancer cells

Publication number: DE19736691
Publication date: 1999-02-25
Inventor: GIESING MICHAEL PROF DR MED (DE)
Applicant: GIESING MICHAEL PROF DR MED (DE)
Classification:
- international: **C12Q1/68; C12Q1/68; (IPC1-7): C12Q1/68; G01N33/68**
- european: C12Q1/68M6B
Application number: DE19971036691 19970822
Priority number(s): DE19971036691 19970822

Also published as:

 WO9910528 (A1)
 EP1007740 (A1)
 US7056660 (B1)
 EP1007740 (A0)
 CA2301962 (A1)

Report a data error here

Abstract of DE19736691

Characterising and identifying disseminated and metastatic cancer cells using RNA and DNA comprises examining a body fluid sample for at least one cancer-specific gene (I) and at least one cancer-associated gene (II). An independent claim is also included for agents used in the new process, preferably in test and/or diagnostic kits.

Data supplied from the **esp@cenet** database - Worldwide